Treatment of Isoniazid-Resistant Pulmonary Tuberculosis
Abstract
Background : As an effective regimen for isoniazid (INH)-resistant pulmonary tuberculosis, several treatment regimens have been recommended by many experts.In Korea, a standard regimen has not been established for INH-resistant tuberculosis, and the treatment by individual physicians has been performed on an empirical bases.The purpose of the present study was to retrospectively describe the treatment characteristics and evaluate the treatment outcomes of patients with INH-resistant tuberculosis.Materials and Methods : Sixty of 69 patients reported to have INH-resistant tuberculosis from 1994 to 2001 were retrospectively analyzed.Exclusion criteria included: death from other causes, with the exceptions of tuberculosis and incomplete treatment, including a patient's transfer-out.Results : A previous tuberculosis history was found in 28 (46.7%)patients.The sputum smear for acid-fast bacilli was positive in 44 (73.3%) patients, and 30 (50.0%) had cavitary disease.Streptomycin resistance coexisted in 25.0% of isolates.INH was to be prescribed continuously, even after INH resistance was reported, in 86.0% of patients.The treatment regimens were diverse between the † 본 연구는 보건복지부 보건의료기술진흥사업의 지원에 의하여 이루어진 것임.(00-PJ1-PG1-CH03-0001)
Read the paper
Related studies
- Deciphering the Resistome of the Widespread Pseudomonas aeruginosa Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing
- Laboratory-based nationwide surveillance of antimicrobial resistance in Ghana
- Phenotypic characterization of an international Pseudomonas aeruginosa reference panel: strains of cystic fibrosis (CF) origin show less in vivo virulence than non-CF strains
- Incidence and factors associated with development of phlebitis: results of a pilot study cohort
- Efficacy of triple therapy with a proton pump inhibitor, levofloxacin, and amoxicillin as first-line treatment to eradicate Helicobacter pylori
- Ten-Day versus 14-Day Levofloxacin-Containing Triple Therapy for Second-Line Anti-Helicobacter pyloriEradication in Taiwan
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.